FOLH1 and hepatocellular carcinoma: Given PSMA-expression in HCC and its vasculature, 18F-DCFPyL could help fill this unmet need and our trial (NCT05009979), which is now recruiting, along with others in Mayo Clinic NCT04310540 and NCT04762888), in Australia (NCT05095519) and China (NCT05006326), aims to answer this question.